Slide 1: Q3 2023 Results
Q3 2023 Results November 2, 2023 We engineer enzymes
Slide 2: Forward Looking Statements
Forward Looking Statements These slides contain forward-looking statements that involve risks and uncertainties. These statements relate to future events or our future financial or operational performance and involve known and unknown risks, uncertainties and other factors that could cause our actua
Slide 3: Strong Financial Execution Opens Path Towards Profitability
Strong Financial Execution Opens Path Towards Profitability Path to Positive Cash Flow Around End of 2026 Commercialization of ECO Synthesis™ Platform Return to Pharmaceutical MFG Growth Reduced Cash Burn >50% Reduction YoY Strong Balance Sheet ($74.6M as of Sep 30, 2023; ~$135M from PAXLOVID™ 2021-
Slide 4: ECO Synthesis Platform: Key Points Drive Conviction
ECO Synthesis™ Platform: 4 Key Points Drive Conviction There is a projected future wave of demand for RNAi therapeutics as additional, large 1 indication assets are approved It will be prohibitively expensive and difficult to manufacture RNAi at commercial 2 scale using traditional phosphoramidite c
Slide 5: ECO Synthesis Virtual KOL Event on December 8, 2023
ECO Synthesis™ Virtual KOL Event on December 8, 2023 External Expert to Share Perspective on Today’s RNAi Therapeutics Manufacturing Landscape and the Potential Value of an Enzymatic Solution Codexis Presenters Guest Speaker Stephen Dilly, MBBS, PhD Chief Executive Officer John Maraganore, PhD Found
Slide 6: Anticipated News Flow for ECO Synthesis Platform
Anticipated News Flow for ECO Synthesis™ Platform • ECO Synthesis™ platform virtual KOL event 2023 • Demonstrate gram-scale synthesis with ECO Synthesis™ technology • ECO Synthesis™ technology enters pre-commercial testing with select 2024 customers • Double-stranded RNA (dsRNA) ligase widely availa
Slide 7: Q3 2023 Key Results Reiterating 2023 Guidance
Q3 2023 Key Results Reiterating 2023 Guidance (Excluding enzyme sales related to PAXLOVID™) $M, Except Per Share Amounts Q3 2023 Q3 2022 Product Revenue1 $5.4 $15.1 $30M–$35M R&D Revenue Total Revenue1 $3.9 $9.3 $6.4 $21.5 Product Revenue1 Cost of Product Revenue1 $2.2 $6.9 Product Gross Margin1 58%
Slide 8: Approaching the End of 2023 in a Position of Financial Strength
Approaching the End of 2023 in a Position of Financial Strength • Reiterating 2023 revenue and gross margin guidance • Pharmaceutical Manufacturing business expected to return to sustained growth in 2024 • Funding for key ECO Synthesis™ platform milestones through anticipated commercialization • Pat
Slide 9: Nasdaq: CDXS www.codexis.com
Nasdaq: CDXS www.codexis.com